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1 Introduction
Diagnostic tests are important for early detection and guiding treatment of various diseases.
A gold standard test, if one exists, ideally provides deﬁnitive examination of disease status,
but often results in high cost and can be invasive. To counter these drawbacks, less expensive
or invasive diagnostic tests are often used for the primary assessment. The accuracy of a
diagnostic test can be evaluated and assured by comparing it to the deﬁnitive gold stan-
dard test. Statistics such as sensitivity and speciﬁcity, which respectively account for the
proportion of true positives and true negatives, have been commonly used when both the
scale of a diagnostic test and true disease status are binary. The Receiver Operating Char-
acteristic (ROC) curve plots a test’s sensitivity against its false negative rate (1-speciﬁcity)
when the test is in either an ordinal- or continuous-scale, and the area under the ROC curve
has been long served as a composite index to describe the discriminatory property of a such
test. Zhou, Obuchowski, and McClish (2002) provided a comprehensive account of statistical
methods for a two-class disease diagnosis, when the true disease status is either the presence
or absence of the disease.
In medical practice, there are situations in which the presence or absence of the dis-
ease is not suﬃcient in describing and presenting the severity and progress of the disease.
For instance, in the study of Alzheimer’s disease (AD), patients are diagnosed by autopsy
as in low likelihood of AD, intermediate likelihood of AD, or high likelihood of AD. The
deﬁnitive diagnosis for diﬀerential likelihood indicates AD neuropathology severity, which
may be reﬂected in the degree of cognitive or neuropsychological decline, and may have an
impact on the decision of nursing and treatment plans. Diagnostic tests capable of discern-
ing patients among these three classes of severity are then of clinical importance. In the
literature, the ROC methodology has been extended to three-class disease status problems
by several authors (Scurﬁeld, 1996; Mossman, 1999; Dreiseitl, Ohno-Machado, and Binder,
2000, Obuchowski, 2005, Nakas and Yiannoutsos, 2004 and 2006, and Xiong et al., 2006).
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Analogous to the two-way ROC curve, Scurﬁeld (1996) deﬁned the three-way ROC
surface as a graph built on the three true classiﬁcation rates. If we denote Dˆ and D as the
rated and true disease status, the three axes of the surface are the three correct classiﬁcation
rates P (Dˆ = k | D = k), for k = 1, 2, 3. There was no direct account to the six false
classiﬁcation rates P (Dˆ = k1 | D = k2), for k1 = k2. By varying the decision rules imposing
upon a diagnostic test T to determine Dˆ, points on the surface are obtained from the
contingency tables between Dˆ and D. For either an ordinal- or continuous-scaled T , if a
higher value of T corresponds to a higher value of D, the decision rule is deﬁned by a pair
of ordered decision thresholds (d1, d2), such that Dˆ = 1 if T ≤ d1, Dˆ = 2 if d1 < T ≤ d2,
and Dˆ = 3 if T > d2. The points (1, 0, 0), (0, 1, 0) and (0, 0, 1) are on every ROC surface,
and the lines connecting them result in the surface corresponding to a test without any
discriminatory power among the three classes. The surface corresponding to a perfect test
is the surface of a unit cube. The volume under the ROC surface can be a useful index
for the accuracy of a three-class diagnostic test. It has been shown that the volume under
the ROC surface equals the probability that diagnostic measurements of any three patients,
one from each class, are in an correct order. The volume under the ROC surface of 1/6
corresponds to a test without discriminatory power, and the value of 1 indicates a perfect
test. We note that two tests can have similar volumes under the ROC surfaces, but diﬀerent
ROC surfaces, for instance, one test may diﬀerentiate disease category 1 very well while the
other test may do better in diﬀerentiating disease category 3. Caution must be taken when
doing the comparison between two ROC volumes.
In practice, it is plausible that only a subgroup of patients who initially are tested
subsequently receives the deﬁnitive assessment for disease status. Subjects may refuse or
simply are not capable of participating in the deﬁnitive examination. The mechanism by
which patients are selected for veriﬁcation may be variable. For example, in the study of
Alzheimer’s disease, the deﬁnitive examination is done through a brain autopsy. Patients
might still be alive resulting in not being veriﬁed, or they died but no autopsy was performed.
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The selection for an autopsy may depend on the degree of cognitive impairment, which may
also aﬀect the clinical diagnosis of Alzheimer’s disease. In the assessment of diagnostic
accuracy, omission of those nonveriﬁed cases can seriously bias the estimate, and the bias is
referred to as veriﬁcation bias (Begg and Greenes, 1983).
There have been methods proposed in the literature to account for the presence of
veriﬁcation bias for a two-class disease status. Gray et al. (1984) and Zhou (1996) both
derived the maximum likelihood estimation for the area under the ROC curve when disease
veriﬁcation is subject to selection bias. Harel and Zhou (2006) adopted a multiple imputation
framework. Alonzo and Pepe (2005) proposed and compared imputation and reweighting
bias-corrected estimators of ROC curves and area under the ROC curve for continuous
tests. Kosinski and Barnhart (2003), and Rotnitzky et al. (2006) suggested a method for
correcting for non-ignorable veriﬁcation bias. In this paper, we extend the methodology
to the three-class disease status problems. We formulate the presence of veriﬁcation bias
into the likelihood-based framework. The proposed approach is ﬂexible in allowing for the
selection mechanism to depend on initial test results and/or any relevant discrete baseline
covariates. Methods for comparing diagnostic tests in the presence of veriﬁcation bias have
also been developed.
The rest of the paper is organized as the following. We introduce the motivating re-
search of Alzheimer’s disease in Section 2. In Section 3, we propose our method when the
selection is related to the test results, and further incorporate discrete baseline covariates
into the proposed method in Section 4. We provide an extension to the comparison between
two volumes under the ROC surfaces in the presence of diﬀerential veriﬁcation in Section 5.
In Section 6, we apply the proposed method to the motivating application on Alzheimer’s
disease described in Section 2. In Section 7, we conduct an extensive simulation to demon-
strate ﬁnite-sample performance of the proposed method. The simulation is set up to cover
diﬀerent true volumes under the ROC surfaces. We discuss some future research directions
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in Section 8.
2 The study of Alzheimer’s Disease
The National Alzheimer’s Coordinating Center (NACC) is funded to facilitate collaborative
research and maintain a database of information collected by the Alzheimer’s Disease Centers
(ADCs) throughout the United States of America. These centers have conducted clinical
and laboratory research on the causes and clinical courses of Alzheimer’s disease (AD). Most
patients at ADCs were referred or self-referred for evaluation of possible dementia, and they
were followed over time with periodic clinical evaluation and cognitive testing. For patients
who die, permission for brain autopsy was sought.
The deﬁnitive examination of Alzheimer’s disease was based on the extent of neuritic
plaques and neuroﬁbrillary tangles, the hallmarks of AD, at brain autopsy. The NIA/Reagan
Institute criteria, based on the frequency of both plaques and tangles in the neocortex to link
to the severity of AD pathology, were graded as no or low (D = 3), intermediate (D = 2),
or high likelihood (D = 1) of dementia being due to AD. The NIA criteria were absent for
patients still alive or who died but had no brain autopsy. The search for clinical diagnostic
tools of AD has long been needed and initiated to ensure prompt health care and treatment
to AD patients.
In the study, a patient’s cognitive function was measured by the latest Mini-Mental
State Examination (MMSE) score recorded prior to death. The MMSE (Folstein, Folstein,
and McHugh, 1975), is a screening tool that evaluates orientation to place, orientation to
time, registration, attention and concentration, recall, language, and visual construction. It
is scored as the number of correctly completed items, and could range from 0 (too impaired
even to answer questions) to 30 (perfect score, cognitively intact). For elderly adults (the
group of patients normally at a higher risk for AD), MMSE scores were used by Reisberg et
al. (2003) and Just (2004), to assess patients with either no AD (MMSE>26: dMMSE=4),
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mild AD (15≤MMSE≤26: dMMSE=3), moderate AD (10≤MMSE≤14: dMMSE=2), or
severe AD (MMSE<10: dMMSE=1). This MMSE-based clinical diagnosis, referred to as
dMMSE, provides a gateway for AD assessment. An alternative approach for AD assessment
is through clinical evaluation for dementia (CDD) by clinicians. With access to various
neuropsychological, cognitive and medical image assessments, experienced clinicians were
able to coordinate the information for the evaluation of dementia. Based on the degree
of abnormal cognition, patients were categorized into one of the three groups, namely AD
dementia (CDD=1), mild cognitive impairment (CDD=2), or non-dementia (CDD=3).
Among a total of 18,838 patients in a subset of a NACC dataset, only 2,497 had died
and agreed to brain autopsy. The selection for autopsy veriﬁcation was clearly dependent of
patients’ performance on dMMSE and CDD. For instance, based on dMMSE scores, 28.9%
of patients with the diagnosis of severe AD were veriﬁed with an autopsy, while only 14.3%,
9.5%, and 9.2% of patients respectively diagnosed as moderate, mild, and no AD underwent
an autopsy. The veriﬁcation rate increased with the severity of the assessment. For CDD, the
proportions of veriﬁcation are respectively 15.4%, 9.0%, and 11.0% for patients determined
as AD dementia, mild cognitive impairment, and non-dementia. In this obvious presence of
diﬀerential veriﬁcation among patient groups, the accuracy of using dMMSE and CDD as
diagnostic tools for AD severity is of interest, as well as the comparison between the two.
To further explore the data, we note that the study participants came from eight distinct
ADCs across the United States. Depending on the majority of patient characteristics, which
might vary geographically, veriﬁcation rates may diﬀer across centers. Figure 1 shows the
veriﬁcation rates across the eight centers for each of the classiﬁcation determined by dMMSE
and CDD. It is clear to see that the probability of being veriﬁed varies not only among the
test categories, but also among the centers. For instance, the rate of veriﬁcation obviously
decreased with the dMMSE classiﬁcation for the eighth ADC, whereas the rates of veriﬁcation
when dMMSE=1 or dMMSE=4 were about twice as much the rates when dMMSE=2 or
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dMMSE=3, for the third ADC. In the evaluation of the overall accuracy of dMMSE and
CDD, it may be more plausible to account for center diﬀerences in veriﬁcation. On the
other hand, some researchers believe that the correlation between the test measurement
(dMMSE or CDD) and the autopsy result would vary across diﬀerent centers, partly due
to the diﬀerential dependence of the test and autopsy classiﬁcation on the center. This
predisposition would then lead researchers to focus on the center-speciﬁc evaluation instead
of the overall evaluation.
3 Test-dependent veriﬁcation
For three-class disease status problems, Scurﬁeld (1996) deﬁned the three-way ROC surface
by points whose coordinates are the three correct classiﬁcation rates, over all possible pairs
of ordered decision thresholds. We let T denote an ordinal test measurement ranging from
1 to M, D denote the true disease status, and a higher value of T corresponds to a higher
value of D. For any pair of ordered decision thresholds (d1, d2), where 0 ≤ d1 < d2 ≤ M ,
the following decision rule may be applied: if T ≤ d1 then Dˆ = 1, else if d1 < T ≤ d2 then
Dˆ = 2, else Dˆ = 3. Here Dˆ indicates the random variable of disease diagnosis based on T .
Given (d1, d2) and the independence among study patients, the three correct classiﬁcation
rates, for k = 1, 2, 3, are deﬁned as
P (Dˆ = k | D = k) = P (dk−1 < T ≤ dk | D = k) =
{
0, d¯k−1 > dk∑dk
i=d¯k−1
πik, d¯k−1 ≤ dk , (3.1)
where πik = P (T = i|D = k), d¯k−1 is the smallest integer greater than dk−1, and dk is the
largest integer less than or equal to dk. We specify the boundary conditions as, d0 = 0 and
d3 = M . If the unknown parameters πik in (3.1) are replaced by their estimates, we can
then obtain the estimates of the three correct classiﬁcation rates, and further, construct the
empirical ROC surface over all possible pairs of decision thresholds, (d1, d2). In this section,
we derive the maximum likelihood (ML) estimates of πik’s when diﬀerential veriﬁcation is
present.
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Nakas and Yiannoutsos (2004) used the following notation system and demonstrated
the volume under the ROC surface is given by
θ = P (Y1 < Y2 < Y3) +
1
2
[P (Y1 < Y2 = Y3) + P (Y1 = Y2 < Y3)] +
1
6
P (Y1 = Y2 = Y3),
where Yk indicates the test measurement obtained from the kth disease group, for k = 1, 2, 3.
To describe it in words, the volume under the ROC surface equals the probability that
the measurements T of three randomly chosen patients, one from each disease group, are
correctly ordered. Their results assumed that each study subject had disease veriﬁcation.
With a ﬁnite support of T , the volume θ is equivalent to
θ =
M−2∑
i=1
M−1∑
j=i+1
M∑
k=j+1
πi1πj2πk3 +
1
2
{
M−1∑
i=1
M∑
j=i+1
(πi1πj2πj3 + πi1πi2πj3)
}
+
1
6
M∑
i=1
πi1πi2πi3. (3.2)
Both the ROC surface and its volume can be expressed as functions of πik’s. Following
Bayes’ theorem, we know that
πik = P (T = i|D = k) = τiφki∑M
j=1 τjφkj
, (3.3)
where τi = P (T = i) and φki = P (D = k|T = i), with τM = 1 −
∑M−1
i=1 τi and φ3i =
1− φ1i − φ2i. To estimate πik’s, one may ﬁrst need to have proper estimates (with account
for veriﬁcation bias) for all τi’s and φki’s.
We propose a likelihood-based approach to estimate parameters τ = (τ1, . . . , τM−1) and
φ = (φ1, . . . ,φM), where φi = (φ1i, φ2i). The observed data with a diﬀerential veriﬁcation
status among patients can be summarized as in Table 1. We denote V as the disease
veriﬁcation indicator, which equals one if the patient receives the deﬁnitive examination,
and equals zero otherwise. When V = 0, the patient is not selected for disease veriﬁcation,
and hence, the summarized frequencies are only available for test values collapsed over all
three disease states.
We make the following assumption about the selection mechanism. We assume the
chance of getting veriﬁed is conditionally independent of the unknown true disease status,
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given the test measurement. In other words, P (V |D,T ) = P (V |T ), and it follows P (D|T ) =
P (D|V, T ). Speciﬁcally, P (D|T ) = P (D|V = 1, T ) and φki = P (D = k|T = i, V = 1). This
assumption is a special case of the missing at random (MAR) assumption on the missing
data mechanism proposed by Rubin (1976). The chance of getting veriﬁed, though might
depend on test results, is dealt as the nuisance parameter, and can be excluded from the
likelihood function since it is distinct from the parameters of interest, τ and φ. Conceptually,
the likelihood function is the product of P (T )P (D|T )P (V |D,T ), which is proportional to
P (T )P (D|T, V = 1) under the above assumptions. The log-likelihood function based on the
observed data in Table 1, can then be derived as
l(τ ,φ) =
M∑
i=1
ni log(τi) +
M∑
i=1
3∑
k=1
aki log(φki), (3.4)
for i = 1, . . . ,M . Note that τ and φi, for i = 1, . . . ,M , are distinct parameters, l1(τ ) =∑M
i=1 ni log(τi) and l2i(φi) =
∑3
k=1 aki log(φki) are the log-likelihood functions for multino-
mial distributions, respectively. Thus, the ML estimates for τ and φi, respectively, are
τˆi =
ni
n
, i = 1, . . . ,M, (3.5)
φˆki =
aki
a1i + a2i + a3i
, k = 1, 2; i = 1, . . . ,M, (3.6)
where n =
∑M
i=1 ni. The observed Fisher information matrix deﬁned on (τ ,φ) is a block
diagonal matrix given by
I(τ ,φ) = diag(I1(τ ), I21(φ1), . . . , I2M(φM)),
where I1(τ ) and I2i(φi) are respectively the observed Fisher’s information matrix on the
log-likelihood l1(τ ) and l2i(φi). The ML estimates of πik can be obtained by replacing τi and
φki in (3.3) by τˆi and φˆki. Subsequently substituting the unknown parameters πik in (3.2)
by their ML estimates through the Bayes’ theorem, we can then obtain the ML estimator θˆ
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for the volume under the ROC surface as
θˆ =
∑M−2
i=1
∑M−1
j=i+1
∑M
k=j+1 τˆiτˆj τˆkφˆ1iφˆ2jφˆ3k(∑M
i=1 τˆiφˆ1i
)(∑M
i=1 τˆiφˆ2i
)(∑M
i=1 τˆiφˆ3i
) +
∑M−1
i=1
∑M
j=i+1 τˆiτˆ
2
j φˆ1iφˆ2jφˆ3j + τˆ
2
i τˆjφˆ1iφˆ2iφˆ3j
2
(∑M
i=1 τˆiφˆ1i
)(∑M
i=1 τˆiφˆ2i
)(∑M
i=1 τˆiφˆ3i
)
+
∑M
i=1 τˆ
3
i φˆ1iφˆ2iφˆ3i
6
(∑M
i=1 τˆiφˆ1i
)(∑M
i=1 τˆiφˆ2i
)(∑M
i=1 τˆiφˆ3i
) . (3.7)
This estimate is equivalent to the one proposed by Nakas and Yiannoutsos (2004) when no
veriﬁcation bias exists. By the use of the Delta method (Agresti, 1990, p56-58), the variance
of θˆ, can be estimated as
∂θT
∂τ
I−11 (τ )
∂θ
∂τ
+
∂θT
∂φ1
I−121 (φ1)
∂θ
∂φ1
+ . . . +
∂θT
∂φM
I−12M(φM)
∂θ
∂φM
, (3.8)
evaluated at τ = τˆ and φi = φˆi, where I
−1
1 (τ ), I
−1
2i (φi), ∂θ/∂τ and ∂θ/∂φi are given in the
Appendix.
An alternative way to estimate the variance of θˆ is to use the jackknife method. As
illustrated by Efron and Tibshirani (1993), estimates of θ with the exclusion of a single
patient allows for the estimation of the variance of θˆ as
n− 1
n
[
M∑
i=1
{
b·i(θˆ(4i) − θˆ(·))2 +
3∑
k=1
aki(θˆ(ki) − θˆ(·))2
}]
, (3.9)
where θˆ(ki) is the estimate of θ after deleting a patient with V = 1, T = i, and D = k,
for k = 1, 2, 3, θˆ(4i) is the estimate of θ after deleting a patient with V = 0, T = i, and
θˆ(·) = (1/n)
(∑M
i=1 b·iθˆ(4i) +
∑3
k=1 akiθˆ(ki)
)
.
4 Incorporating covariates in the selection mechanism
For some studies, such as the one on Alzheimer’s Disease, there often exist baseline covariates
X, which may either inter-correlate with the test value T and true disease status D, or
aﬀect the selection for veriﬁcation. We focus our discussion on the incorporation of discrete
covariates with a ﬁnite total number of covariate patterns. The covariate-speciﬁc volume
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under the ROC surface can be estimated by the method derived in the previous section to
each pattern of X. If the goal is to obtain a common index of accuracy across all covariate
patterns, the method derived in the previous section needs to be modiﬁed to account for the
possible covariate-dependent diﬀerential veriﬁcation.
Assume that X comprises of P discrete covariates, each with Nj possible categories,
for j = 1, . . . , P , and we let N =
∏P
j=1 Nj indicate the total number of diﬀerent covari-
ate patterns of X. We further assume that X is a random sample from a discrete space
(X1, . . . ,XN) with probabilities δ = (δ1, . . . , δN). The parameter πik in (3.3) is then given
by
πik =
N∑
j=1
P (T = i,X = Xj | D = k) =
∑N
j=1 τijφkijδj∑M
l=1
∑N
j=1 τljφkljδj
, (4.1)
where τij = P (T = i | X = Xj), φkij = P (D = k | T = i,X = Xj), and δj = P (X = Xj),
for i = 1, . . . ,M , j = 1, . . . , N , and k = 1, 2, 3. Deviated from the previous derivation,
the distributions of T and [D | T ] are now related to the covariates X. With a similar
ignorable assumption on the selection mechanism, except now in the presence of X, we have
P (V |D,T,X) = P (V |T,X), which can be shown leads to P (D|T,X) = P (D|T,X, V = 1),
equivalently φkij = P (D = k | T = i,X = Xj, V = 1).
In order to estimate θ in (3.2) and the coordinates of the empirical ROC surface in (3.1),
both of which are functions of the πik’s, we need to obtain the ML estimates of τij, φkij, and
δj within each pattern of covariates. We note that for the observed data with X = Xj, the
jth contingency table among random variables, V , D, and T can be formed, and the data
structure is an analog of the observed data displayed in Table 1, except for an additional
subscript j for all elements. The log-likelihood function can be derived as
l(τ ,φ, δ) =
N∑
j=1
{
M∑
i=1
nij log(τij) +
M∑
i=1
3∑
k=1
akij log(φkij) + nj log(δj)
}
, (4.2)
where nij, akij, and nj are respectively the total number of patients with T = i and X = Xj,
the total number of veriﬁed patients with D = k, T = i and X = Xj, and the total number
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of patients with X = Xj. The ML estimates for parameters δ, τ , and φ are
δˆj =
nj
n
, j = 1, . . . , N − 1, (4.3)
τˆij =
nij
nj
, i = 1, . . . ,M − 1; j = 1, . . . , N, (4.4)
φˆkij =
akij
a1ij + a2ij + a3ij
, k = 1, 2; i = 1, . . . ,M ; j = 1, . . . , N, (4.5)
where n =
∑N
j=1 nj. The ML estimates of πik can be obtained by replacing δj, τij and φkij
in (4.1) respectively by δˆj, τˆij and φˆkij.
For any given pair of decision thresholds, (d1, d2), the ML estimates of the three correct
classiﬁcation rates are then given by
Pˆ (Dˆ = k | D = k) =
{
0, d¯k−1 > dk∑dk
i=d¯k−1
πˆik, d¯k−1 ≤ dk , (4.6)
for k = 1, 2, 3. These three correct classiﬁcation rates can then be used as coordinates in the
construction of the empirical three-way ROC surface. Similarly, substituting the unknown
parameters πik by their ML estimates in (3.2), we can then obtain the ML estimator θˆ for
the volume under the ROC surface. The corresponding variance estimator can be obtained
by either Jackknife method or the Fisher’s information method as described in the previous
section.
5 Comparison between volumes under ROC surfaces
When comparing two diagnostic tests, one of the eﬃcient designs is a paired design in which
patients receive both tests for the diagnosis of the same disease. Since for a test, the volume
under the ROC surface can be used to measure its accuracy, the diﬀerence between the two
volumes naturally provides a means to assess the diagnostic discrepancy in accuracy. In
order to account for possible correlation in addition to adjust for veriﬁcation bias, we need
to modify our derivations. We ﬁrst assume test T1 ranges from 1 to M1, and test T2 ranges
12
Hosted by The Berkeley Electronic Press
from 1 to M2. The intermediate parameter ηijk is given by
ηijk = P (T1 = i, T2 = j|D = k) = αijψkij∑M1
s=1
∑M2
t=1 αstψkst
, (5.1)
where αij = P (T1 = i, T2 = j), and ψkij = P (D = k|T1 = i, T2 = j). For k = 1, 2, 3, we then
let πik1 = P (T1 = i|D = k) =
∑M2
j=1 ηijk, for i = 1, . . . ,M1, and πik2 = P (T2 = i|D = k) =∑M1
j=1 ηjik, for i = 1, . . . ,M2. Given πik1’s, the volume under the ROC surface for T1 is
θ1 =
M1−2∑
i=1
M1−1∑
j=i+1
M1∑
k=j+1
πi11πj21πk31+
1
2
{
M1−1∑
i=1
M1∑
j=i+1
(πi11πj21πj31 + πi11πi21πj31)
}
+
1
6
M1∑
i=1
πi11πi21πi31,
(5.2)
and given πik2’s, the volume under the ROC surface for T2 is
θ2 =
M2−2∑
i=1
M2−1∑
j=i+1
M2∑
k=j+1
πi12πj22πk32+
1
2
{
M2−1∑
i=1
M2∑
j=i+1
(πi12πj22πj32 + πi12πi22πj32)
}
+
1
6
M2∑
i=1
πi12πi22πi32,
(5.3)
The observed data with diﬀerential selection for deﬁnitive examination is shown in
Table 2. The cross classiﬁcation of T1 and T2 gives a total of M1M2 frequency counts for the
group of veriﬁed patients. By assuming P (V |D,T1, T2) = P (V |T1, T2), similar to the one in
Section 3, we can obtain the observed log-likelihood as
l(α,ψ) =
M1∑
i=1
M2∑
j=1
mij log(αij) +
M1∑
i=1
M2∑
j=1
3∑
k=1
ckij log(ψkij), (5.4)
where α = [α11, . . . , α1M2 , α21, . . . , α2M2 , . . . , αM11, . . . , αM1(M2−1)], ψij = (ψ1ij, ψ2ij), and
ψ = (ψ11, . . . ,ψM1M2). The ML estimates for α and ψ, respectively, are
αˆij =
mij
m
, i = 1, . . . ,M1; j = 1, . . . ,M2, (5.5)
ψˆkij =
ckij
c1ij + c2ij + c3ij
, k = 1, 2; i = 1, . . . ,M1; j = 1, . . . ,M2, (5.6)
where m =
∑M1
i=1
∑M2
j=1 mij. Subsequently substituting the unknown parameters αij and ψkij
by their ML estimates to obtain estimates ηˆijk, and πˆik1 and πˆik2, we can ultimately compute
the ML estimates θˆ1 from (5.2), and θˆ2 from (5.3).
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The observed Fisher information matrix deﬁned on (α,ψ) is a block diagonal matrix
given by
I(α,ψ) = diag(I1(α), I211(ψ11), . . . , I2M1M2(ψM1M2)),
where I1(ψ) and I2ij(ψij) are respectively the observed Fisher information matrix on the
log-likelihood l1(α) =
∑M1
i=1
∑M2
j=1 mij log(αij) and l2ij(ψij) =
∑3
k=1 ckij log(ψkij). By the
Delta method, we can estimate the variance-covariance matrix Σθˆ of θˆ = [θˆ1, θˆ2]
T by
∂θT
∂α
I−11 (α)
∂θ
∂α
+
∂θT
∂ψ11
I−1211(ψ11)
∂θ
∂ψ11
+ . . . +
∂θT
∂ψM1M2
I−12M1M2(ψM1M2)
∂θ
∂ψM1M2
, (5.7)
evaluated at α = αˆ and ψij = ψˆij, where I
−1
1 (α), I
−1
2ij (ψij), ∂θ/∂α and ∂θ/∂ψij are given
in the Appendix. Another alternative way to estimate Σθˆ is by the Jackknife method. With
the exclusion of a single patient, the variance-covariance matrix can be estimated as
Σˆθˆ =
n− 1
n
[
M1∑
i=1
M2∑
j=1
{
d·ij(θˆ(4ij) − θˆ(·))(θˆ(4ij) − θˆ(·))T +
3∑
k=1
ckij(θˆ(kij) − θˆ(·))(θˆ(kij) − θˆ(·))T
}]
,
where θˆ(kij) is the estimate of θ = [θ1, θ2]
T after deleting a patient with V = 1, T1 = i,
T2 = j, and D = k, for k = 1, 2, 3, θˆ(4ij) is the estimate of θ after deleting a patient with
V = 0, T1 = i, T2 = j, and θˆ(·) = (1/n)
(∑M1
i=1
∑M2
j=1 d·ijθˆ(4ij) +
∑3
k=1 ckijθˆ(kij)
)
.
A test of statistical signiﬁcance of diagnostic accuracy diﬀerence can then be calculated
as z = cT θˆ/
√
cT Σˆθˆc, where the contrast c = [1,−1]T . Given the asymptotic normality of
the ML estimate θˆ, the test statistic z asymptotically follows a standard normal distribution.
6 The analysis of NACC data
We now analyze the NACC dataset to evaluate the accuracy of using Mini-Mental State
Examination and clinical diagnosis of dementia in assessing AD severity. Figure 2 displays
the empirical ROC surfaces for dMMSE and CDD, after accounting for the veriﬁcation
bias. The graphs were drawn with respect to the three correct classiﬁcation rates, across all
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possible decision thresholds. We note that both plots are bounded in a unit cube, and both
surfaces contain the points of (1, 0, 0), (0, 1, 0), and (0, 0, 1).
Based on dMMSE scores, our estimate of the volume under the ROC surface was 0.4027
with standard deviation of 0.0104 by both the information and Jackknife approach. Without
account for diﬀerential veriﬁcation, the estimate, proposed by Nakas and Yiannoutsos (2004),
based only on veriﬁed patients was 0.4035 with bootstrap (size=100) standard deviation of
0.0108. Only a slight diﬀerence was present between the two estimates, which might be
due to a small discrepancy between center-speciﬁc estimates with and without considering
veriﬁcation bias, as shown in Figure 3. Our estimate was more eﬃcient due to the account
for both veriﬁed and unveriﬁed cases in the analysis. For CDD, the discrepancy between
the two estimates became noticeable. Our estimate of the ROC surface volume was 0.3707
with standard deviation of 0.0091 by both the information and Jackknife approach, while the
estimate ignoring unveriﬁed patients was 0.3503 with standard deviation of 0.0094. For both
the analyses of dMMSE and CDD, our estimates of standard deviation are quite close between
the information and Jackknife approach. By comparing the point estimates, dMMSE seems
to have a better power than CDD in assessing the severity of AD, after accounting for
veriﬁcation bias.
To properly infer and compare the accuracy between dMMSE and CDD, we then worked
on the joint cross-classiﬁcation table by the two tests and veriﬁcation status. This observed
cross table implicitly permits the incorporation of any correlation structure between dMMSE
and CDD (due to a paired design) in the calculation of our statistics. After accounting for
diﬀerential veriﬁcation, the diﬀerence between the two volumes under the ROC surfaces was
0.0124 with 95% conﬁdence limits of (-0.0089, 0.0337) by the information method and the
conﬁdence limits of (-0.0091, 0.0339) by the Jackknife approach. There was no signiﬁcant
discrepancy in the accuracy between dMMSE and CDD, and the same conclusion was drawn
by the two proposed approaches for variance estimation. We note that, despite the uniﬁed
15
http://biostats.bepress.com/uwbiostat/paper315
MMSE procedure may have shown a competitive power in assessing the severity of AD, the
clinical implication based on CDD may still be indispensable. The diagnosis based on CDD
not only guides the assessment of AD severity, but is aimed to direct the etiology of dementia
to other variants.
Finally, in order to account for center diﬀerences in veriﬁcation selection and in the cor-
relation between the test and autopsy examination, we include the AD center as a covariate
in the evaluation of dMMSE and CDD. The center-speciﬁc estimates of the volumes under
the ROC surfaces were drawn in the ﬁrst row of Figure 3. There was clear variation across
the eight research centers in the accuracy of using dMMSE scores to assess AD severity, and
the diﬀerences among centers became less prominent in the assessment of CDD. An overall
evaluation of CDD, by combining the empirical information from all centers, may reasonably
be used to achieve a higher eﬃciency in the estimate as compared to the center-speciﬁc ones.
After adjusting for the center eﬀect, the volume under the ROC surface was estimated as
0.3961 (with standard deviation of 0.0120) for dMMSE and 0.3932 (with standard deviation
of 0.0117) for CDD. The volume estimate for dMMSE was a bit inﬂated if center diﬀerences
in veriﬁcation were ignored, while on the other hand, the estimate for CDD was reduced if
the center eﬀect was overlooked. Based on the asymptotic property of ML estimates, the
95% conﬁdence limits for volumes under the ROC surfaces, after adjusting for the center
eﬀect, were (0.3726, 0.4196) and (0.3702, 0.4161), respectively for dMMSE and CDD. The
exclusion of the null value of 1/6 in both conﬁdence limits suggests that both dMMSE and
CDD possess discriminatory power in assessing the severity of AD.
7 Simulation study
We conducted sets of simulation study to examine the performance of the proposed method.
The data were ﬁrst generated as follows. We simulated a 5-point rating scale test measure-
ment for each of the three disease states. The distributions of test categories can diﬀer across
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diﬀerent disease status, and the ﬁve diﬀerent probabilities were chosen and given in Table 3,
aimed to have diverse true volumes under the ROC surfaces. After generating the complete
data, we then randomly chose a subgroup of patients and set their disease status as unknown.
The selection probability was chosen to be an increasing function of a test result. The selec-
tion probabilities for veriﬁcation are (1) P (V = 1|T = 1) = 0.4, (2) P (V = 1|T = 2) = 0.6,
(3) P (V = 1|T = 3) = 0.7, (4) P (V = 1|T = 4) = 0.8, (5) P (V = 1|T = 5) = 0.9.
For each run, we assumed a sample of 300 patients for each disease status, and the results
were summarized over 1,000 replications. Table 4 displays the true volumes under the ROC
surfaces, and the performance of the proposed estimate. The bootstrap approach proposed
by Nakas and Yiannoutsos (2004), without account for diﬀerential veriﬁcation, was also
implemented with 100 bootstrap samples for the purpose of comparison. It is clear to see in
Table 4, that our estimates were up to 5.4% more accurate than naive estimates ignoring non-
veriﬁed cases, and the improvement remained in four of the ﬁve diﬀerent parameter settings.
When distributions of test scores were the same among the three disease groups (no diagnostic
power), the bias of ignoring diﬀerential veriﬁcation was gone, as expected. The 95% coverage
of conﬁdence intervals was almost successfully retained by both the Fisher’s information
and Jackknife approach of standard deviation estimation. A poor coverage appeared when
the selection mechanism was ignored. We further compared the proposed information and
Jackknife approach for the estimation of standard deviation with the empirical estimates.
The Jackknife estimates were consistently closer to the empirical estimates, suggesting that
standard deviation estimated by Jackknife method may be better than the one estimated
by the information method. Consistently larger estimates in standard deviation by the
information approach also resulted in a wider coverage in conﬁdence intervals, as compared
to the one by the Jackknife method.
To further investigate the validity and robustness of the proposed approach against the
violation of the MAR veriﬁcation, we modiﬁed the selection probabilities to have them vary
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with the true disease states. We had P (V = 1|T = i,D = k) = 0.3 + 0.1i + 0.05k, for
i = 1, . . . , 5 and k = 1, 2, 3. The results were summarized in Table 5 over 1,000 replications.
We observed that the absolute biases increased when the MAR assumption was violated;
nevertheless, our estimates remained to be more accurate than the naive estimates. The
coverage of 95% conﬁdence intervals was not aﬀected very much by this non-ignorable ver-
iﬁcation. This simulation supports that our estimates remain valid and robust if the MAR
assumption is moderately violated.
For the comparison between volumes under two related ROC surfaces, we extended the
simulation setups to two ordinal-scale tests. We supposed that a disease could be diagnosed
either by a 5-point rating test tool T1, or by another 4-point rating test measurement T2.
We chose ﬁve diﬀerent parameter settings for the joint probability of the two test scores to
achieve a diverse spectrum in the true volumes under the ROC surfaces and their diﬀerences.
The joint probabilities were speciﬁed for each individual cell in the cross table analog to
Table 2 as V = 1. We assumed that the chance for the deﬁnite veriﬁcation depends on
the joint distribution of the two test scores, namely, P (V = 1|T1 = i, T2 = j) = 0.64, for
i, j ≤ 2, P (V = 1|T1 = i, T2 = j) = 0.81, for i, j > 2, and P (V = 1|T1 = i, T2 = j) = 0.72
otherwise. The results were summarized over 1,000 replications in Table 6, with the size of
1,000 patients for each of the three disease groups. In Table 6, each row corresponds to a
speciﬁc distributional setup for T1 and T2, and the true volumes under the ROC surfaces, θ1
and θ2, were designed to diﬀer across rows. It was clear to see that biases in the diﬀerence
between volumes were small in all ﬁve settings. The coverage of conﬁdence intervals was
satisfactorily around 95% by both the information and Jackknife method for the estimation
of the standard deviation.
Several other selection probability and sample sizes had also been chosen in our sim-
ulation, but were skipped for presentation, due to the similar conclusion. We only note
that biases induced by ignoring non-veriﬁed cases in the analysis increased with decreased
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veriﬁcation rates.
8 Discussion
In this paper, the ML estimate of the volume under the ROC surface is derived when deﬁni-
tive disease veriﬁcation is subject to selection. The veriﬁcation bias induced by diﬀerential
selection is numerically demonstrated in the simulation over diﬀerent diagnostic abilities.
Under the consideration of ignorable veriﬁcation, this bias can be adjusted in the framework
of likelihood principle, and the standard deviation for the volume estimate can be obtained
from either the Fisher’s information or Jackknife method. There are limitations in the pro-
posed approach. Like chi-square tests for the analysis of contingency tables, our estimate
is not suitable to handle sparse data, particularly when a zero number of veriﬁed cases is
present for some test measurements. The standard deviation estimated by the information
method would fail if the observed cross table between D and T , e.g. Table 1, for veriﬁed
cases has any zero entry. Similar limitations apply to the extension to the comparison be-
tween two diagnostic tools. It requires a nonzero number of veriﬁed cases for each cross
classiﬁcation of T1 and T2 in Table 2. A more stringent requirement of all positive ckij’s is
needed to carry out the variance estimation by the information method.
We applied the proposed method to the largest national database on Alzheimer’s disease
to compare the relative accuracy between Mini-Mental State Examination and clinical eval-
uation of dementia in grading the severity of Alzheimer’s disease. We found an interesting
result that Mini-Mental State Examination and clinical evaluation of dementia had similar
accuracy in predicting neuropathological severity of Alzheimer’s disease, even though the
clinical evaluation of dementia was much more expensive and required more clinical infor-
mation. The results were drawn from the recruitment of the eight ADCs across the United
States, and may need further investigation by community-based studies. Nevertheless, the
clinical evaluation of dementia still has important implication in guiding the diagnosis of
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dementia to other variants, such as Lewy body disease and vascular dementia.
The proposed methodology may be easily modiﬁed to diagnostic problems with more
than three disease classes. There are some issues that remain open for future investigation.
For instance, in the presence of veriﬁcation bias, how can the accuracy of a continuous test
measurement be evaluated? Rotnitzky et al. (2006) developed a doubly robust estimation for
the area under the ROC curve that adjusts for selection to veriﬁcation for markers measured
on any scale. The extension of their methodology to the volume under the ROC surface
may be helpful in diagnostic medicine when the severity of the disease is of interest. The
comparison of accuracy between tests measured in diﬀerent scales would be another direction
to pursue. Furthermore, the relaxation of the assumption about ignorable veriﬁcation by
presuming the selection to veriﬁcation directly associated with the true disease status, may
be more plausible as adjusting for veriﬁcation bias.
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Table 1: Observed data of an ordinal-scaled test data
T = 1 T = 2 · · · T = M
V = 1 D = 1 a11 a12 · · · a1M
D = 2 a21 a22 · · · a2M
D = 3 a31 a32 · · · a3M
V = 0 b·1 b·2 · · · b·M
Total n1 n2 · · · nM
Table 2: Observed data of the two ordinal-scaled test data.
T1 = 1 · · · T1 = M1
T2 = 1 · · · T2 = M2 · · · T2 = 1 · · · T2 = M2
V = 1 D = 1 c111 · · · c11M2 · · · c1M11 · · · c1M1M2
D = 2 c211 · · · c21M2 · · · c2M11 · · · c2M1M2
D = 3 c311 · · · c31M2 · · · c3M11 · · · c3M1M2
V = 0 d·11 · · · d·1M2 · · · d·M11 · · · d·M1M2
Total m11 · · · m1M2 · · · mM11 · · · mM1M2
Table 3: Probabilities for test scores in the three disease groups.
P (T = 1, T = 2, T = 3, T = 4, T = 5)
D = 1 D = 2 D = 3
I (0.20, 0.20, 0.20, 0.20, 0.20) (0.20, 0.20, 0.20, 0.20, 0.20) (0.20, 0.20, 0.20, 0.20, 0.20)
II (0.30, 0.30, 0.20, 0.10, 0.10) (0.10, 0.20, 0.25, 0.25, 0.20) (0.05, 0.05, 0.20, 0.30, 0.40)
III (0.50, 0.20, 0.20, 0.05, 0.05) (0.10, 0.25, 0.30, 0.25, 0.10) (0.05, 0.05, 0.20, 0.20, 0.50)
IV (0.80, 0.05, 0.05, 0.05, 0.05) (0.05, 0.10, 0.70, 0.10, 0.05) (0.05, 0.05, 0.05, 0.05, 0.80)
V (0.95, 0.02, 0.01, 0.01, 0.01) (0.02, 0.03, 0.90, 0.03, 0.02) (0.01, 0.01, 0.01, 0.02, 0.95)
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Table 4: Volume under a single ROC surface with MAR veriﬁcation, averaged over 1,000
replications.
Our estimates Naive estimates
Absolute Standard deviation % CI coverage Absolute % CI
θ bias Empirical Delta Jackknife Delta Jackknife bias coverage
I 0.1667 0.0010 0.0157 0.0167 0.0166 96.4 96.4 0.0010 95.7
II 0.3903 0.0012 0.0233 0.0248 0.0233 96.4 95.2 0.0217 80.8
III 0.5164 0.0008 0.0249 0.0277 0.0252 97.2 95.4 0.0196 88.0
IV 0.7270 0.0001 0.0276 0.0296 0.0273 96.3 95.0 0.0392 76.7
V 0.9312 0.0004 0.0166 0.0202 0.0160 98.5 93.1 0.0122 90.8
Table 5: Volume under a single ROC surface with non-ignorable veriﬁcation, averaged over
1,000 replications.
Our estimates Naive estimates
Absolute Standard deviation % CI coverage Absolute % CI
θ bias Empirical Delta Jackknife Delta Jackknife bias coverage
I 0.1667 0.0051 0.0153 0.0156 0.0154 93.3 92.9 0.0047 92.6
II 0.3903 0.0032 0.0228 0.0242 0.0226 96.1 95.1 0.0195 85.3
III 0.5164 0.0058 0.0247 0.0271 0.0245 96.1 93.7 0.0145 89.9
IV 0.7270 0.0059 0.0266 0.0291 0.0268 96.6 95.5 0.0263 85.9
V 0.9312 0.0029 0.0164 0.0202 0.0162 98.5 94.6 0.0090 92.5
Table 6: The numerical comparison between two ROC surfaces, with Δθ = θ1 − θ2.
Absolute bias Delta method Jackknife
θ1 θ2 Δθ for Δθ CI coverage % CI length CI coverage % CI length
0.1667 0.1667 0.0000 0.0003 94.6 0.0441 94.7 0.0442
0.1667 0.4680 -0.3013 0.0005 95.9 0.0573 95.9 0.0575
0.1667 0.7693 -0.6026 0.0004 95.8 0.0578 95.9 0.0580
0.4693 0.4680 0.0013 0.0006 94.1 0.0711 94.2 0.0713
0.4693 0.7693 -0.3000 0.0004 95.8 0.0710 96.0 0.0714
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Figure 1: The selection rates for veriﬁcation across eight ADCs and categories by dMMSE
(left) and CDD (right).
Figure 2: The empirical ROC surfaces of dMMSE (left) and CDD (right), after accounting
for veriﬁcation bias. The three axes are the three correct classiﬁcation rates.
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Figure 3: The means and 95% asymptotic conﬁdence intervals of the center-speciﬁc ROC
volume estimates for dMMSE and CDD. The top two graphs were with account for veriﬁca-
tion bias, while the bottom two used only veriﬁed cases. The dashed line is the null line of
no discrimination power.
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